Invention Grant
- Patent Title: Heterocyclic compound
-
Application No.: US15799379Application Date: 2017-10-31
-
Publication No.: US10087150B2Publication Date: 2018-10-02
- Inventor: Takahiro Sugimoto , Shinkichi Suzuki , Hiroki Sakamoto , Masami Yamada , Minoru Nakamura , Makoto Kamata , Kenichiro Shimokawa , Takuto Kojima
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Hamre, Schumann, Mueller & Larson, P.C.
- Priority: JP2015-129043 20150626; JP2015-206797 20151020
- Main IPC: C07D265/22
- IPC: C07D265/22 ; C07D413/14 ; C07D413/04 ; C07D413/06 ; C07D413/10 ; C07D417/06 ; C07D471/04 ; C07D491/107 ; C07F7/02
Abstract:
The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
Public/Granted literature
- US20180050996A1 HETEROCYCLIC COMPOUND Public/Granted day:2018-02-22
Information query
